Taken together, the overall findings on TERT alterations imply that TERT promoter mutations would better predict the outcome of patients with early-stage HCC treated with surgery, whereas TERT expression may be more associated with the prognosis of later-stage HCC patients eligible for non-surgical treatments. The gene discussed is TERT; the disease is hepatocellular carcinoma.